Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences Inc (INBX) is a clinical-stage biopharmaceutical innovator developing targeted therapies for oncology and rare diseases through advanced protein engineering. This dedicated news hub provides investors and industry observers with comprehensive access to official corporate communications and verified developments.
Our curated collection features INBX's latest press releases, regulatory filings, and clinical trial updates. Track progress across therapeutic programs including multivalent biologics and optimized antibody candidates designed through the company's proprietary modular platforms. Stay informed about strategic partnerships, research milestones, and financial disclosures that shape INBX's position in biopharmaceutical innovation.
Key updates include clinical development timelines, intellectual property advancements, and collaborative research initiatives. All content is sourced directly from company filings and authorized statements to ensure reliability. Bookmark this page for streamlined access to INBX's evolving pipeline and corporate announcements, presented with neutral analysis suitable for both institutional and individual investors.
On June 30, 2022, Inhibrx, Inc. (Nasdaq: INBX) announced the completion of Phase 1 dose escalation for its novel targeted 4-1BB agonist, INBRX-105, in combination with Keytruda®. The trial, involving 30 patients, indicated a favorable safety profile and durable responses. Additionally, the company secured $60 million in funding through its Loan Agreement with Oxford Finance, adjusting its cash balance to approximately $176 million. The next phase of trials is set to include around 90 patients, with initial results expected in early 2023.
Inhibrx, Inc. (Nasdaq: INBX) will present details on its INBRX-109 Phase 2 trial for conventional chondrosarcoma at the 2022 ASCO Annual Meeting from June 3-7, 2022. The trial aims to establish a placebo-controlled methodology for evaluating INBRX-109, a DR5 agonist antibody. Preliminary Phase 1 results showed efficacy in 89% of patients, with a median progression-free survival of 7.4 months. The presentation, led by Dr. Sant P. Chawla, will take place on June 5, 2022, from 9 a.m. to 11 a.m. CST, and the poster will be available online.
Inhibrx Inc. announces favorable topline results from a Phase 1 clinical trial of INBRX-101, a recombinant human AAT-Fc fusion protein for treating alpha-1 antitrypsin deficiency (AATD). The study involved 31 patients and showed no severe drug-related adverse events, with mild and reversible issues reported. The drug achieved an average functional alpha-1 antitrypsin (AAT) level of 40.4 µM after the third dose, surpassing the current standard of care's 17.8 µM. Inhibrx believes INBRX-101 could reduce infusion frequency significantly, offering a more convenient treatment option.
Inhibrx, Inc. (Nasdaq: INBX) reported its Q1 2022 financial results and corporate updates on May 9, 2022. The company reported cash and equivalents of $143.5 million, an increase from $131.3 million at year-end 2021. R&D expenses rose to $24.9 million, compared to $16.4 million in Q1 2021. General and administrative expenses also increased to $5.1 million. The net loss for Q1 2022 was $31.3 million ($0.80 per share), up from $19.3 million ($0.51 per share) in Q1 2021. Recent highlights include FDA orphan-drug designation for INBRX-101 and a $130 million loan agreement amendment.
Inhibrx, Inc. (Nasdaq: INBX) announced the establishment of a Scientific Advisory Board (SAB) for its clinical program INBRX-101, aimed at treating alpha-1 antitrypsin deficiency (AATD). The board consists of leading experts in AATD, who will collaborate with Inhibrx's management to advance INBRX-101 towards regulatory approval. The drug has shown promise as a potentially best-in-class treatment, addressing a significant unmet need in AATD, which affects about 100,000 patients in the U.S. Current standard treatments require inconvenient weekly dosing, while INBRX-101 may allow for monthly administration.
Inhibrx (Nasdaq: INBX) announced that late-breaking data on INBRX-101 will be presented at the American Thoracic Society (ATS) 2022 Conference from May 13-18, 2022, in San Francisco, CA. The oral presentation, led by Mark Brantly, focuses on a novel recombinant AAT-Fc fusion protein for patients with Alpha-1 Antitrypsin Deficiency (AATD). It will occur on May 16, while a related poster presentation will take place on May 17. AATD affects about 100,000 individuals in the US, leading to serious lung issues. INBRX-101 has shown promising early results in an ongoing Phase 1 trial.
Inhibrx, Inc. (Nasdaq: INBX) announced the presentation of data from its clinical programs INBRX-121 and INBRX-130 at the 2022 AACR Annual Meeting, scheduled from April 8-13, 2022, in New Orleans, LA. INBRX-121 enhances NK cell tumor killing, while INBRX-130 is a bispecific antibody targeting 5T4 antigen on solid tumors. Both platforms aim to expand Inhibrx's oncology pipeline and improve treatment outcomes. Posters will be available on-demand from April 8 to July 13, 2022, on AACR's website and Inhibrx's site.
Inhibrx, Inc. (Nasdaq: INBX) announced that the FDA has granted orphan-drug designation for INBRX-101 to treat alpha-1 antitrypsin deficiency (AATD). This designation acknowledges the unmet medical need for new therapies in AATD, which affects approximately 100,000 patients in the U.S. INBRX-101 is designed for once-monthly dosing and aims to improve AAT levels significantly. Orphan designation offers benefits, including financial incentives and potential seven years of market exclusivity upon approval, enhancing Inhibrx's position in the biotech sector.
Inhibrx, Inc. (Nasdaq: INBX) reported its financial results for Q4 and FY 2021, highlighting a net loss of $21.2 million for Q4, or $0.55 per share, compared to $17.6 million in Q4 2020. The annual net loss increased to $81.8 million, or $2.15 per share, from $76.1 million in FY 2020. The company had cash and equivalents of $131.3 million as of December 31, 2021. Recent highlights include FDA orphan-drug designation for INBRX-109 and initial Phase 1 results for INBRX-106, now expected to announce further data in H2 2022.
Inhibrx, Inc. (Nasdaq: INBX) has amended its loan agreement with Oxford Finance, enhancing its financial flexibility amid a challenging equity market. The amendment allows for up to $130 million in new term loans, with $40 million available immediately and additional funding contingent upon key clinical trial developments. The revised terms extend loan maturity to January 2027 at an interest rate of 8.19%. This deal strengthens Inhibrx's balance sheet and supports ongoing clinical programs, including INBRX-105 and INBRX-101.
